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Abstract
Background—Despite women suffering a disproportionate burden of colon cancer mortality, 
few studies have examined gender differences in evidence-based treatment, especially in poorer 
states like Alabama.
Objective—To describe colon cancer treatment in older patients diagnosed in Alabama by 
gender.
Methods—Colon cancer patients 65 years and older diagnosed in 2000–2002 were identified 
from the Alabama Statewide Cancer Registry (N = 1785). Treatment was identified from Medicare 
claims for 1999–2003. Outcomes were (1) receipt of surgery and adjuvant 5-fluorouracil 
chemotherapy (5FU) and (2) 5FU treatment duration (0–4, 5–7, and >7 months). Generalized 
Estimating Equation (GEE) models were used to determine significant gender differences, 
adjusting for clustering at the reporting hospital level, and controlling for race, age, stage, 
comorbid conditions, census tract–level socioeconomic variables, and adverse chemotherapy 
effects (when analyzing 5FU duration).
Results—Overall, 93.9% of the patients received surgery. Of stage II–III patients undergoing 
surgery, 60.4% stage III and 25.6% stage II patients received 5FU. Compared with men, women 
were more likely to have surgery (95.5% vs. 92.2%, p = 0.003), less likely to have 5FU (38.6% vs. 
45.2%, p = 0.02), and more likely to have 0–4 months of 5FU (32.9% vs. 24.9%, p = 0.05). 
Gender differences were significant for having chemotherapy (adjusted odds ratio [aOR] 0.78, 
confidence interval [CI] 0.61–1.00, p = 0.049), but not for having 0–4 months of 5FU when 
adjusting for adverse effects (aOR 1.36, CI 0.95–1.94, p = 0.09).
Conclusions—In Alabama, some gender differences in stage-specific colon cancer treatment are 
worth further scrutiny.
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Introduction
THE AMERICAN CANCER SOCIETY (ACS) estimates that there will be more than 140,000 new cases of 
colorectal cancer in 2012.1 Although men are more likely to develop colorectal cancer, 
women suffer a disproportionate mortality burden from this disease, especially older and 
African American women.2–5 About 70% of colorectal cancer cases are cases of colon 
cancer.1 Adequate treatment of colon cancer is important to potentially cure and/or prolong 
survival; therefore, differences in treatment may explain differences in survival across 
patients’ groups. Treatment guidelines recommend surgery followed by adjuvant 
chemotherapy as the standard of treatment for stage III colon cancer.6,7 For stage II colon 
cancer, colectomy may be all that is required, except for adjuvant chemotherapy for patients 
with higher risk for recurrence. Standard chemotherapy for colon cancer at the time of this 
study was 5-fluorouracil (5FU)-based chemotherapy usually administered in six cycles of 
21–28 days each.8 In a large randomized controlled trial, patients who received 5FU-based 
adjuvant chemotherapy had a relative risk reduction of 40% for recurrence and of 33% for 
mortality.9
Several studies have investigated whether cancer patients receive recommended treatment 
for their disease presentation, mostly focusing on differences by race and age.10–15 Fewer 
studies have addressed the colon cancer treatment differences in regard to gender.16 To 
address this research gap, the objective of this study was to describe the treatment of colon 
cancer by gender in older patients diagnosed in Alabama. In particular, we investigated 
whether surgery and adjuvant chemotherapy were received and how long chemotherapy 
treatment lasted for Medicare beneficiaries diagnosed in a 4-year period from 2000 to 2003.
Materials and Methods
The current analysis is part of a larger study to assess cancer-directed treatment in Medicare 
patients with breast, colorectal, lung, or prostate cancer. The study was approved by the 
institutional review boards of the University of Alabama at Birmingham and the Centers for 
Disease Control and Prevention.
A cohort of 3435 Alabama residents 65 years old and older diagnosed with colon cancer in 
the period from January 1, 2000, to December 31, 2002, was identified from the Alabama 
Statewide Cancer Registry (ASCR). ASCR is Alabama’s population-based cancer registry 
which is supported by the Centers for Disease Control and Prevention’s National Program of 
Cancer Registries. The data collected by the ASCR have been recognized as high quality by 
the North American Association of Central Cancer Registries with a designation of silver 
certification in 2003 for case completeness greater than 90%.17,18
We obtained 1999–2003 Medicare claims for inpatient, outpatient, and physician visits for 
the cohort described above. Thus, we had at least 1 year of claims data for the period before 
the cancer diagnosis to determine comorbid conditions, and for least 1 year of follow-up 
postdiagnosis to determine cancer treatment received. Because administrative claims (and, 
thus, the opportunity of examining treatment) are available only for beneficiaries in fee-for-
service plans, we excluded 856 cases of beneficiaries who were not on fee-for-service plans. 
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Of the remaining 2579 colon cancer patients, we excluded those with histology types not 
consistent with colon cancer (N = 24), not black or white (N = 21), with stage IV (N = 300), 
and stage 0 or missing (N = 449). The final cohort consisted of 1785 Alabama beneficiaries 
with stage I–III colon cancer. Compared with these, the 1650 beneficiaries excluded from 
analysis were more likely to be black (25.8% vs. 15.7%, p < 0.0001) and to be older than 75 
years (58.2% vs. 53.5%, p = 0.005).
Colon cancer treatment
We identified surgery using the International Classification of Disease Ninth Revision 
(ICD-9) codes 45.7x, 45.8x, 48.4x, 48.5x, 48.6x, and 48.7x, and the Current Procedure 
Terminology (CPT)/Healthcare Common Procedure Coding System (HCPCS) codes 
44140-44147, 44150-44156, 44160, 45110-45114, 45116, 45119-45121, 45123, 45160, and 
45170. We identified chemotherapy using ICD-9 codes V58.1, V66.2, 99.25, 99.24, 99.28, 
and 00.10, and CPT/HCPCS codes J9190, 96400, 96405, 96406, 96408, 96410, 96412, 
96414, 96420, 96422, 96423, 96425, 96440, 96445, 96450, 96520, 96530, 96542, 96545, 
and 96549. We searched for relevant codes in the period starting 2 months before the 
diagnosis date reported by ASCR and ending 1 year after that date. We considered the 
following outcomes:
1. Having surgery;
2. Having adjuvant chemotherapy (5FU) after surgery for those with stage II and III 
colon cancer; and
3. Duration of 5FU chemotherapy among those with stage II and III colon cancer who 
started this treatment after surgery.
Treatment duration was defined as the time from the first and last claim for that treatment. 
Similar to Neugut et al.,11 we identified patients who received 0–4 months of chemotherapy 
(i.e., 120 days or less), 5–7 months (i.e., 121–210 days), and more than 7 months (i.e., 211 
days or more). Furthermore, we identified adverse events in the year postdiagnosis that were 
potentially related to chemotherapy (infection or fever, neutropenia or thrombocytopenia, 
anemia or transfused red blood cells, nausea emesis or diarrhea, abnormal electrolytes, 
dehydration, malnutrition, constitutional symptoms or nonspecific complication of 
treatment, deep vein thrombosis and pulmonary embolism) or were found to be rarely 
associated with chemotherapy in clinical trials (fractures and dislocations, asthma and 
chronic obstructive pulmonary disease, renal failure, thyroid disorders, and headaches).19,20
We used Generalized Estimating Equation (GEE) models to determine whether there were 
significant differences by gender for having surgery and adjuvant chemotherapy and for 
having chemotherapy 0–4 months. The GEE models accounted for the clustering of patients 
within reporting hospitals. This statistical technique has been used in various cancer studies 
of treatment and outcomes to control for clustering, for example, at the patient, the 
physician, the reporting hospital, or the neighborhood level.21–30 All analyses were done 
using SAS (SAS software, version 9.1; SAS Institute, Cary, NC) including PROC 
GENMOD with REPEATED option. Independent variables included race, age, stage, 
comorbidity index, rural–urban residence, and census tract socioeconomic status. In the 
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model predicting 5FU duration of 0–4 months, we included those side effects that had 
significantly different frequencies for men and women. We used the Charlson Comorbidity 
Index31 to identify debilitating or serious diseases that may have hindered the probability of 
getting colon cancer treatment. To measure socioeconomic status we created binary 
indicators for living in census tracts with 35% or more of the population being black, 20% or 
more of the population living below the poverty line, and 45% or more of the population 
with a high school education or less. These cutoffs were based on the value of the 75th 
percentiles for these variables.
Results
Of the 1785 colon cancer survivors in this study, 48.7% were male and 51.3% female, 
84.3% were white and 15.7% were black, and 46.5% were 75 years old or older (Table 1). 
Cases were equally distributed across stage I to III disease, and about 70% had at least one 
comorbid condition. Approximately 25% died by the end of the follow-up period (2003) 
with less than 8% dying within 9 months of diagnosis. Men and women did not differ in 
many demographic and disease characteristics, except that women were younger than men 
(59.7% in 65- to 74-year-old group vs. 47% of men, p < 0.0001). However, 17.4% of the 
women were black compared with 14% of the men (p = 0.05), and 33.2% of the women had 
stage III disease versus 29.2% of the men (p = 0.09).
Overall 93.9% of the colon cancer survivors received surgery and of them 33.9% had 
adjuvant chemotherapy (Table 2). Of the 1182 patients with stage II–III disease who 
received surgery, 45.1% received chemotherapy and 41.7% received 5FU. As expected, use 
of chemotherapy was higher for persons with stage III colon cancer (60.4%) than for 
patients with stage II (25.6%) (Table 2). Moreover, among the 492 stage II and III patients 
receiving 5FU-based adjuvant chemotherapy, the mean number of days on treatment was 
150.2 (SD = 78.07), and 28.9% received 0–4 months of 5FU with no difference by disease 
stage (Table 2). Moreover, more than 70% had symptoms such as anemia, nausea, emesis, or 
diarrhea, and about half suffered from dehydration or infection and fever (Table 3).
Women were slightly more likely than men to have surgery (95.5% vs. 92.2%, p = 0.003), 
and were less likely to have 5FU-based adjuvant chemotherapy (38.6% vs. 45.2%, p = 0.02). 
Among those who received it, women were more likely than men to have 0–4 months 
(32.9% vs. 24.9%, p = 0.05) and less likely to have 5–7 months of adjuvant chemotherapy 
(49.4% vs. 60.2%, p = 0.01) (Table 2). Women were more likely than men to experience 
dehydration (63.8% vs. 47.8%, p = 0.0004). They were also more likely to have symptoms 
or conditions unrelated to chemotherapy such as thyroid disorder (16.9% vs. 7.2%, p = 
0.001) and fractures or dislocation (8.6% vs. <4.4%, p = 0.02). Other symptoms had similar 
frequencies for men and women (Table 3).
In the analyses adjusted for age, disease stage, existence of other comorbid conditions, and 
census tract socioeconomic variables, gender differences remained statistically significant 
except for surgery. Women had significantly lower odds of 5FU-based adjuvant 
chemotherapy (odds ratio [OR] 0.78, confidence interval [CI] 0.61–1.00, p = 0.049; Table 4) 
and higher odds of receiving fewer than 120 days of treatment (OR 1.52, CI 1.07–2.15; not 
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shown). When controlling for side effects, however, the gender difference in receiving fewer 
than 120 days of 5FU was not significant (OR 1.36, CI 0.95–1.94, p = 0.09; Table 4).
No differences in treatment were found between white and black cancer survivors. 
Moreover, while survivors 75 years old or older were less likely to receive chemotherapy 
(27.4% vs. 58.8%, OR 0.24, CI 0.19–0.31), no differences were found in the duration of 
5FU by age (Tables 2 and 4). In addition, having higher stages of disease was associated 
with higher odds of having surgery and chemotherapy, and with no significant differences in 
the likelihood of having chemotherapy duration of 0–4 months (Table 4). Finally, census 
tract variables were not associated with treatment (Table 4).
Discussion
Among colon cancer cases diagnosed in Alabama in 2000–2002, we found that most 
received surgery and almost 42% received adjuvant 5FU chemotherapy. Among those with 
stage II–III disease who started this therapy, almost 30% received 0–4 months and about 
70% received treatment for a longer period. Chemotherapy was used more frequently in 
patients with stage III colon cancer (60.4%). We also found that women were significantly 
less likely to receive chemotherapy compared with men and more likely to have a shorter 
duration of treatment. This finding is of concern because adjuvant chemotherapy for colon 
cancer patients with stage II and III disease significantly improves outcomes.8,9
Our results concur with those of Paulson et al.16 who found that among 30,975 Medicare 
beneficiaries with colon cancer patients diagnosed in SEER areas in 1996–2002, women 
with stage III disease were less likely to receive adjuvant chemotherapy after surgical 
resection than men (51.5% vs. 59.5%, p < 0.001). However, Neugut et al.11 did not find 
gender differences in duration of 5FU among older Medicare beneficiaries with stage III 
colon cancer diagnosed in 1995–1999. In an earlier time period (1992–1996), Dobie et al.15 
found that female Medicare beneficiaries with stage III colon cancer were significantly less 
likely to receive chemotherapy and were less likely to complete chemotherapy, defined as 5 
months or more, compared with men. However, the gender disparity in completion of 
chemotherapy was not significant after adjusting for age, stage, comorbidities, hospital 
readmissions, and socioeconomic information.15 We previously found similar gender 
differences in duration of chemotherapy among older persons diagnosed with rectal cancer 
in Alabama around the same time period (1999–2003).32
The fact that women were less likely to receive adjuvant chemotherapy and have shorter 
duration of treatment is concerning. Poor health and older age are often reasons for 
underutilization of cancer treatment.33,34 However, compared with men, women were 
younger and they did not have more comorbid conditions in the year before the cancer 
diagnosis. However, they were more likely to have thyroid disorder or fractures possibly 
before starting chemotherapy. Thus, women may be more likely to have some conditions 
that indicate frailty, making physicians reluctant to prescribe chemotherapy. Other factors 
that affect underuse of cancer treatments are related to beliefs in treatment efficacy, 
concerns about side effects, the relation with physicians, the treatment preferences of the 
physicians, and several other reasons that we could not ascertain in this study and that may 
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vary by gender.34–37 Furthermore, women were not more likely than men to come from 
disadvantaged neighborhoods, and thus may not have been more likely to refuse 
chemotherapy for economicreasons. Therefore, research into reasons why chemotherapy use 
in women is low warrants further research.
Once chemotherapy is started, it is important to consider the impact adverse events may 
have on its duration. Schrag et al.14 found that between 7% and 13% of colon cancer 
patients 65 years and older receiving chemotherapy were hospitalized for treatment-related 
adverse events such as neutropenia, mucositis, diarrhea, sepsis, and dehydration. Cen et al.20 
also reported high rates of chemotherapy-associated adverse events among Medicare 
beneficiaries with colon and rectal cancer in 2003 to 2005, especially for patients older than 
70 years. All of these symptoms may cause a patient to prematurely stop treatment, leading 
to suboptimal outcomes. While some have reported that chemotherapy may be less tolerated 
in women,38–40 Cen et al.20 did not report differences in side effects by gender. Our 
findings, instead, showed that some side effects are more prevalent in women (e.g., 
dehydration) and that these may account for women having shorter courses of treatment. 
However, we have to consider that our findings are limited by a small sample size; 
investigating such gender differences in larger cohorts of colon cancer patients is thus 
warranted. The higher occurrence of some side effects in older women raises important 
questions about the administration of chemotherapy; for example, whether women are more 
likely than men to receive treatment doses not appropriate for their weight. Our claims data 
do not allow us to investigate whether this was the case, but future studies should investigate 
such potential differences in chemotherapy administration by gender.
Compared with previous studies of Medicare beneficiaries with colon cancer, Alabama 
beneficiaries received more adjuvant 5FU chemotherapy after surgery during the study 
period. For example, we found that among stage III colon cancer patients almost 64% had 
claims for chemotherapy. Neugut et al.11 found that 54% of stage III colon cancer patients 
diagnosed in 1995–1996 received adjuvant chemotherapy. Similarly Dobie et al.15 found 
that 55% of stage III colon cancer Medicare beneficiaries started chemotherapy. Similar 
rates were found by Paulson et al.16 in the period 1996–2002. Hu et al.41 for the period 
1991–2005 found that 64.4% of Medicare beneficiaries received chemotherapy, and 62% 
completed it. Kahn et al.42 found that among patients diagnosed in 2003–2005 in seven U.S. 
states including Alabama, 75% of those with stage III disease received chemotherapy. 
Among these patients, about 60% had more than 150 days of chemotherapy. We found 
similar patterns for rectal cancer patients in Alabama for the same time period: almost 65% 
of stage III rectal cancer patients had chemotherapy.32 Duration of chemotherapy is also 
comparable to what was found in other studies. We found that only 26% of those with stage 
II–III disease had less than 4 months of chemotherapy, with about 55% receiving 
chemotherapy for 5–7 months. Others found among stage III colon cancer patients that 
64%–78% had at least 5 months (150 days) of treatment.11,15,42
Other results of our analyses are of interest. We did not find racial differences in colon 
cancer treatment in this population. These findings concurred with Hofmann et al.12 who 
reported no significant treatment differences among black and white colorectal cancer 
patients of all ages, and with Chagpar et al.13 who found no difference in guideline 
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concordant care for colon cancer patients of all ages in the period 2003–2007. However, 
according to Dimou et al.,10 black patients were less likely than white patients to have 
surgical treatment for stage I cancer, although surgery is the recommended treatment for this 
stage. We also found differences by age in the use of chemotherapy, although we found no 
difference in duration of this treatment. This is similar to others,11,13,16 although Neugut et 
al.11 found that older patients also had shorter courses of chemotherapy. Schrag et al.14 
found that patients who were older were as likely to want chemotherapy as their younger 
counterparts, and suggested that underutilization of chemotherapy among older patients may 
not be medically justified. The literature further supports this suggestion. Another study 
found that not receiving chemotherapy due to patient refusal was the case for less than a 
third of patients, while advanced age and comorbid conditions were reasons for 11.4% and 
21.6% of patients, respectively.43 Other explanations for decreased utilization of 
chemotherapy in older patients included financial and geographic barriers to care, physician 
knowledge and attitudes, as well as patient preferences.14
This study has several limitations. Information on treatment is derived from claims data and 
not from medical records. Therefore, identification of procedures depends on accurate 
billing and coding. However, other studies have found, for example, that use of 
chemotherapy can be reliably identified from these databases.44 In addition, with these data, 
we cannot identify dose reductions or discontinuation of treatment prescribed by the 
physician. Symptoms and conditions that may be related to chemotherapy were identified 
for a 1-year period after diagnosis, and we cannot ascertain whether they occurred after 
treatment was initiated. However, we found that they were significantly more common 
among persons who had received chemotherapy. Lastly, during the study period 5FU-based 
chemotherapy with leucovorin or levamisole was the standard of care for colon cancer. 
Currently, 5FU remains the backbone of colorectal cancer chemotherapy, but accompanying 
drugs include oxaliplatin and irinotecan. We expect, however, that results are relevant to the 
new standard chemotherapy combinations because the side effects we described as those 
associated with 5FU and not the other drugs.
In conclusion, in Alabama, one of the poorest states in the United States where medical 
resources are more limited than in richer states, colon cancer patients received treatment 
comparable to or better than patients in other US states. However, our findings indicate that 
oncology providers may need to be alert to individual patient characteristics, including 
gender, which might lead to premature discontinuation of chemotherapy. In particular, 
attention should be given to specific side effects of therapy that may be more prevalent in 
women and lead to shorter courses of 5FU-based chemotherapy. Suboptimal duration of 
chemotherapy affects colon cancer survival.8 Some studies clearly show such gender 
mortality disparities in colon cancer patients,3 and others find no disparities when adjusting 
for treatment received.16 More work is needed to elucidate the role of chemotherapy in 
reported gender disparities of colon cancer outcomes.
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Table 1
Demographic and Clinical Characteristics of Colon Cancer Patients with Nonmetastatic Disease: Percentages 
and p Values for Bivariate Associationsa
All
Sex
Male Female
N = 1785 N = 870 N = 915 pb
Sex
 Male 48.7 — —
 Female 51.3 — —
Race 0.05
 White 84.3 86.0 82.6
 Black 15.7 14.0 17.4
Age < 0.0001
 65–74 years 53.5 47.0 59.7
 ≥ 75 years 46.5 53.0 40.3
Stage 0.09
 I 31.8 33.9 29.7
 II 37.0 36.9 37.0
 III 31.3 29.2 33.2
Comorbidity index 0.22
 0 30.7 32.1 29.4
 ≥ 1 69.3 67.9 70.6
Vital status
 Deceased at the end of follow-up (2003) 25.4 26.2 24.7 0.46
 Deceased within 9 months from diagnosis 7.9 7.2 8.5 0.31
Census track socioeconomic status
 Percent black ≥ 35% 26.2 24.2 28.0 0.07
 Percent with less than high school ≥ 45% 29.5 30.9 28.1 0.19
 Percent living below poverty line > 20% 24.3 22.5 25.9 0.10
a
Data from the Alabama Statewide Cancer Registry and Medicare: Alabama 2000–2002.
b
p value obtained using chi-squared tests.
J Womens Health (Larchmt). Author manuscript; available in PMC 2015 June 22.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Oliver et al. Page 12
Ta
bl
e 
2
Su
rg
er
y 
an
d 
A
dju
va
nt 
Ch
em
oth
era
py
 fo
r C
olo
n C
an
cer
 Pa
tie
nts
 w
ith
 N
on
me
tas
tat
ic 
Di
sea
se 
by
 Pa
tie
nt 
Ch
ara
cte
ris
tic
s, a
nd
 p 
V
al
ue
s f
or
 B
iv
ar
ia
te
 
A
ss
oc
ia
tio
ns
a
Su
rg
er
y a
m
on
g 
17
85
st
ag
e 
I–
II
I p
at
ie
nt
s
5F
U
c  
ch
em
ot
he
ra
py
a
m
o
n
g 
11
82
st
ag
e 
II
–I
II
 p
at
ie
nt
s
w
ith
 su
rg
er
y
M
on
th
s o
f c
he
mo
the
rap
y a
mo
ng
49
2 
sta
ge
 II
–I
II
 p
at
ie
nt
s o
n 
5F
U
Al
l
0–
4
5–
7
≥ 
7
%
p
%
p
%
p
%
p
%
p
A
ll
93
.9
41
.7
28
.9
54
.9
16
.3
Se
x
0.
00
3
0.
02
0.
05
0.
01
0.
39
 
M
al
e
92
.2
45
.2
24
.9
60
.2
14
.9
 
Fe
m
al
e
95
.5
38
.6
32
.9
49
.4
17
.7
R
ac
e
0.
30
0.
70
0.
48
0.
14
0.
27
 
W
hi
te
94
.1
41
.5
29
.5
53
.4
17
.1
 
B
la
ck
92
.5
42
.9
25
.6
62
.2
<
 1
3b
A
ge
0.
51
<
 0
.0
00
1
0.
03
0.
04
0.
92
 
65
–7
4
93
.5
58
.8
25
.6
58
.2
16
.1
 
≥ 
75
94
.2
27
.4
34
.7
48
.9
16
.5
St
ag
e
<
 0
.0
00
1
<
 0
.0
00
1
0.
12
0.
86
0.
10
 
I
87
.1
—
—
—
—
 
II
96
.4
25
.6
33
.3
54
.3
12
.3
 
II
I
97
.8
60
.4
26
.7
55
.1
18
.2
Co
m
or
bi
di
ty
 in
de
x
0.
01
<
 0
.0
00
1
0.
56
0.
60
1.
00
 
0
93
.0
45
.7
29
.5
54
.2
16
.3
 
≥ 
1
96
.0
33
.0
26
.8
56
.9
16
.3
Ce
ns
us
 tr
ac
k
 
so
ci
oe
co
no
m
ic
 st
at
us
Pe
rc
en
t b
la
ck
 
po
pu
la
tio
n
 
≥ 
35
%
93
.8
0.
91
43
.7
0.
39
28
.9
0.
99
59
.9
0.
16
11
.3
0.
06
 
<
 3
5%
93
.9
41
.0
28
.9
52
.9
18
.3
J Womens Health (Larchmt). Author manuscript; available in PMC 2015 June 22.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Oliver et al. Page 13
Su
rg
er
y a
m
on
g 
17
85
st
ag
e 
I–
II
I p
at
ie
nt
s
5F
U
c  
ch
em
ot
he
ra
py
a
m
o
n
g 
11
82
st
ag
e 
II
–I
II
 p
at
ie
nt
s
w
ith
 su
rg
er
y
M
on
th
s o
f c
he
mo
the
rap
y a
mo
ng
49
2 
sta
ge
 II
–I
II
 p
at
ie
nt
s o
n 
5F
U
Al
l
0–
4
5–
7
≥ 
7
%
p
%
p
%
p
%
p
%
p
Pe
rc
en
t p
op
ul
at
io
n 
w
ith
 
le
ss
 th
an
 h
ig
h 
sc
ho
ol
 
≥ 
45
%
93
.0
0.
29
42
.1
0.
85
29
.1
0.
93
52
.3
0.
45
18
.5
0.
36
 
<
 4
5%
94
.3
41
.5
28
.7
56
.0
15
.2
Pe
rc
en
t p
op
ul
at
io
n 
liv
in
g
 
be
lo
w
 p
ov
er
ty
 li
ne
 
>
 2
0%
94
.0
0.
92
46
.5
0.
05
32
.1
0.
32
57
.7
0.
44
10
.2
0.
02
 
≤ 
20
%
93
.9
40
.1
27
.6
53
.8
18
.6
a
D
at
a 
fro
m
 th
e 
A
la
ba
m
a 
St
at
ew
id
e 
Ca
nc
er
 R
eg
ist
ry
 a
nd
 M
ed
ic
ar
e:
 A
la
ba
m
a 
20
00
–2
00
2.
 T
he
 p
 
v
al
ue
s w
er
e 
ob
ta
in
ed
 u
sin
g 
ch
i-s
qu
ar
ed
 te
sts
.
b O
m
itt
ed
 d
ue
 to
 sm
al
l n
um
be
rs
.
c O
f a
ll 
pa
tie
nt
s w
ith
 a
dju
va
nt 
ch
em
oth
era
py
, 9
0.1
% 
ha
d 5
FU
 ch
em
oth
era
py
 ba
sed
 tre
atm
en
t. 5
FU
, 5
-fl
uo
rou
rac
il.
J Womens Health (Larchmt). Author manuscript; available in PMC 2015 June 22.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Oliver et al. Page 14
Table 3
Adverse Events in Patients with Stage II-III Colon Cancer on 5-Fluorouracil Chemotherapy
All
Sex
Male Female
n = 492 n = 249 n = 243 pa
Chemotherapy related
 Infection or fever 45.9 45.0 46.9 0.66
 Neutropenia or thrombocytopenia 14.2 12.4 16.0 0.25
 Anemia or transfused packed red blood cells 77.6 74.3 81.1 0.07
 Nausea, emesis, or diarrhea 72.8 69.1 76.5 0.063
 Abnormal electrolytes, dehydration 55.7 47.8 63.8 0.0004
 Malnutrition 29.1 27.7 30.4 0.50
 Constitutional symptoms or nonspecific complication of treatment 46.5 47.0 46.1 0.84
 DVT/PE 13.6 10.8 16.5 0.07
Chemotherapy unrelated (only rarely associated
 with chemotherapy use in trials)
 Fractures or dislocation 6.1 <4.4b 8.6 0.02
 Asthma or COPD 14.2 12.8 15.6 0.38
 Renal failure 9.3 10.8 7.8 0.25
 Thyroid disorders 12.0 7.2 16.9 0.001
 Headache 7.5 8.0 7.0 0.66
a
The p value was obtained using chi-squared tests.
bOmitted due to small numbers.
DVT/PE, deep vein thrombosis/pulmonary embolism; COPD, chronic obstructive pulmonary disease.
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Table 4
Adjusted Odds Ratios (95% Confidence Intervals) of Receiving Treatment for Patients With Nonmetastatic 
Colon Cancera
Treatment
Surgery
5FU adjuvant chemotherapy
(Stage II-III, N = 1182)
0–4 months of 5FU
treatment N = 492
OR CI OR CI OR CI
Sex
 Female 1.54 1.00–2.39 0.78 0.61–1.00 b 1.36 0.95–1.94
Race
 Black 0.72 0.37–1.40 0.89 0.59–1.33 0.73 0.42–1.28
Age
 75+ 0.95 0.66–1.36 0.24 0.19–0.31 1.43 0.97–2.11
Stage
 I 1.00 — — — — —
 II 3.76 2.26–6.26 1.00 — 1.00 —
 III 5.93 3.53–9.98 5.06 3.46–7.39 0.70 0.47–1.05
Comorbidity
 ≥ 1 1.68 1.04–2.71 0.59 0.46–0.76 0.89 0.58–1.38
Census track socioeconomic status
 Percent black ≥ 35% 1.02 0.55–1.90 0.91 0.63–1.31 0.84 0.45–1.58
 Percent with less than high school ≥ 45% 0.77 0.52–1.13 0.97 0.70–1.35 0.85 0.55–1.31
 Percent living below poverty line > 20% 1.08 0.59–1.94 1.39 0.95–2.04 1.59 0.96–2.64
Side effects
 Abnormal electrolytes, dehydration — — — — 2.13 1.41–3.24
 Fractures, dislocation — — — — 0.48 0.19–1.22
 Thyroid disorders — — — — 1.48 0.93–2.35
a
Data from the Alabama Statewide Cancer Registry and Medicare: Alabama 2000–2002, Generalized Estimating Equation models. Adjusted ORs 
are derived from logistic models adjusted for all variables listed in the table. Bolded figures highlight a significant difference (p < 0.05).
b
p = 0.049.
OR, odds ratio; CI, confidence interval.
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